Loading organizations...
§ Private Profile · San Francisco, CA, USA
AI-powered platform for document creation and management for life sciences, focused on regulatory submissions and medical writing.
Artos has raised $500K across 1 funding round.
Key people at Artos.
Artos was founded in 2023 by Josh Kim (Founder) and Varun Patel (Founder).
Artos has raised $500K in total across 1 funding round.
Artos is an artificial intelligence software company that provides a document creation and management platform tailored for the life sciences industry. The enterprise software-as-a-service platform enables biotechnology, pharmaceutical, and medical device organizations to draft critical regulatory submissions, including INDs, NDAs, and BLAs, while maintaining source traceability and audit logs. Backed by lead investor Y Combinator, the startup operates with a team of six employees and recently secured $500,000 in pre-seed funding. The company utilizes a subscription-based business model, offering a basic tier at $299 per year for small teams and an enterprise tier at $999 per year for larger organizations. To support its ongoing expansion, the firm is actively hiring for four engineering and product roles. Artos was founded in 2023 by Josh Kim, who previously worked at the University of Chicago Medicine, and Varun Patel.
Artos was founded in 2023 by Josh Kim (Founder) and Varun Patel (Founder).
Artos has raised $500K in total across 1 funding round.
Artos's investors include Y Combinator.
Artos has raised $500K across 1 funding round. Most recently, it raised $500K Seed in February 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Feb 1, 2024 | $500K Seed | — | Y Combinator | Announced |
Key people at Artos.
---
Artos is an AI-powered document authoring platform purpose-built for the life sciences industry, helping pharmaceutical, biotech, and medical device companies accelerate their regulatory and R&D documentation processes. The company’s mission is to transform the traditionally slow, manual, and costly regulatory submission workflow into a fast, automated, and secure process—enabling life sciences teams to focus on innovation rather than paperwork. Artos serves biopharma organizations by automating the creation of critical documents such as INDs, NDAs, BLAs, protocols, investigator brochures, and study reports. By synthesizing complex data from diverse sources and generating high-quality first drafts in minutes, Artos dramatically reduces the time and effort required for regulatory submissions. The company has gained rapid traction, backed by Y Combinator and recognized as a leader in AI-driven medical writing, with growing adoption across the sector.
---
Founded in 2023 by Josh Kim and Varun Patel, Artos emerged from the founders’ firsthand experiences with the inefficiencies of regulatory documentation in life sciences. Josh, with a background in AI and medical device development at UChicago Medicine, teamed up with Varun after collaborating on an AI-based medical product. Their shared frustration with the time-consuming, error-prone process of preparing regulatory submissions led them to build Artos. The platform was born out of a desire to solve a real pain point they had encountered: the months-long cycle of manual drafting, editing, and cross-referencing required for regulatory packages. Early traction came quickly, with Artos being accepted into Y Combinator and gaining attention from leading life sciences organizations for its ability to deliver rapid, high-quality document drafts.
---
---
Artos is riding the wave of generative AI’s transformation of knowledge-intensive industries, particularly in regulated sectors like life sciences. The timing is critical: as regulatory demands grow and drug development timelines compress, companies are under pressure to accelerate submissions without sacrificing quality. Artos leverages advances in agentic AI and automation to meet this need, positioning itself at the intersection of AI, healthcare, and regulatory technology. The platform is influencing the broader ecosystem by setting a new standard for how regulated industries can harness AI—not just for efficiency, but for compliance, traceability, and innovation. As AI adoption accelerates in pharma and biotech, Artos is helping to redefine what’s possible in medical writing and regulatory affairs.
---
Artos is poised to become a foundational tool for life sciences companies navigating the complexities of regulatory submissions. As AI continues to mature and regulatory agencies become more open to digital transformation, Artos is well-positioned to expand its suite of document types, deepen integration with industry data systems, and potentially move into adjacent areas like clinical trial management and regulatory intelligence. The company’s focus on security, accuracy, and ease of use will be key as it scales. In the coming years, Artos could play a pivotal role in accelerating drug development and improving patient access to new therapies—turning the once-burdensome task of regulatory documentation into a strategic advantage. Just as the founders envisioned, Artos is making it possible to author life sciences documents in minutes, not months.
